BACKGROUND: Insulin-like growth factor 2 mRNAbinding protein 2 (IGF2BP2) regulates translation of IGF2, a growth factor that plays a key role in controlling fetal growth and organogenesis including adipogenesis and pancreatic development. In Caucasians, the rs4402960 G>T polymorphism of IGF2BP2 has been shown to predispose to type 2 diabetes (T2D) in multiple populations. In this study, we tested whether rs4402960 G>T and rs11705701 G>A contribute to the development of T2D in a Russian population. METHODS: Both markers were genotyped in Russian diabetic (n = 1,470) and non-diabetic patients (n = 1,447) using a Taqman allele discrimination assay. The odds ratio (OR) for the risk of developing T2D was calculated using logistic regression assuming an additive genetic model adjusted for age, sex, HbA1c, hypertension, obesity, and body mass index (BMI). Multivariate linear regression analyses were used to test genotype-phenotype correlations, and adjusted for age, sex, hypertension, obesity, and BMI. Expression of IGF2BP2 in the visceral adipose tissue was quantified using real-time PCR. The content of IGF2BP2 protein and both its isoforms (p58 and p66) in the adipose tissue was measured using Western blot analysis. RESULTS: There was no significant association between rs4402960 and T2D. Whereas, allele A of rs11705701 was associated with higher T2D risk (OR = 1.19, p < 0.001). Diabetic and non-diabetic carriers of genotype TT (rs4402960) had significantly increased HOMA-IR (p = 0.033 and p = 0.031, respectively). Nondiabetic patients homozygous for AA (rs11705701) had higher HOMA-IR (p = 0.04), lower HOMA-β (p = 0.012), and reduced 2-h insulin levels (p = 0.016). Non-obese individuals (diabetic and non-diabetic) homozygous for either AA (rs11705701) or TT (rs4402960) had higher levels of IGF2BP2 mRNA in the adipose tissue than other IGF2BP2 variants. Also, allele A of rs11705701 was associated with reduced amounts of the short isoform (p58) and increased levels of the long isoform (p66) of the IGF2BP2 protein in adipose tissue of non-obese diabetic and non-diabetic subjects. CONCLUSIONS: IGF2BP2 genetic variants contribute to insulin resistance in Russian T2D patients. The short protein isoform p58 of IGF2BP2 is likely to play an antidiabetogenic role in non-obese individuals.
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IGF2BPs are mainly cytoplasmic, but the presence of two nuclear export signals implies that they attach to their target mRNAs in the nucleus, and facilitate nuclear export of the transcripts to enable protein synthesis at specific locations in the cytoplasm [3] . They form large RNP granules dispersed around the nucleus and in cellular protrusions [4] . The RNP granules move into the cytoplasm. They are enriched with IGF2BPs and other proteins, including those responsible for the secretory pathway, endoplasmic reticulum-associated quality control, and ubiquitin-dependent metabolism. The presence of these proteins thus supports the concept of RNP granules as posttranscriptional operons [5] .
Except for mRNA trafficking, IGF2BPs also control both the translatability and stability of particular mRNAs. IGF2BPs impair translation of leader 3 IGF2 mRNA that exhibits at least six IGFBP-binding elements in the 5' untranslated region (UTR) and one site within the 3'-UTR [1] . The molecular target of rapamycin (mTOR), a key member of PI3K/Akt/p70-S6 kinase 1 signaling (that stimulates cell growth and protein synthesis), has been shown to phosphorylate IGF2BP2 at two sites, which promote IGF2BP binding to the IGF2 leader 3 mRNA 5' UTR [6] .
The physiological role of IGF2BP is still unexplained. In mice, all three forms of IGF2BP are highly expressed in the embryo. Their expression declines with development towards birth, and is low or undetectable in most adult animals [1] . Transgenic overexpression of IGF2BP3 causes subtle morphological alterations in the pancreas [7] . Loss-of-function analysis in Xenopus embryos indicated that the IGF2BP3 orthologue Vg1-RBP is required for establishment of the pancreatic fate within the endoderm [8] .
The IGF2BP2 protein is encoded by 16 exons. The IGF2BP2 gene, located at chromosome 3q27.2, has a very long 125-kb intron, which is by far the largest intron among mammalian species. In genome-wide association studies (GWAS), several single nucleotide polymorphisms (SNPs) situated in this intron showed significant association with type 2 diabetes (T2D) [9] [10] [11] . The IGF2BP2 association has been widely replicated in various Caucasian [12] [13] [14] and Asian [15] [16] [17] [18] [19] populations. Among IGF2BP2 intron 2 SNPs, rs4402960 G>T showed the most significant association with the disease. According to the results of two recent meta-analyses, the rs4402960 polymorphism of the IGF2BP2 gene was related to an increased risk of T2D for T vs. G allele (OR 1.14; 95% CI 1.11-1.16) [20, 21] . In the analysis of different ethnicities, significantly increased risks were found in East Asian, Caucasian, and Indian populations.
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The diabetes-associated allele G of rs4402960 has been found to be linked to decreased earlyphase insulin release, reduced homeostatic model assessment of β-cell function (HOMA-β), lowered fasting insulin, and other indices of impaired pancreatic β-cell function [22] [23] [24] [25] . Also, rs4402960 and rs11705701, located in the promoter of IGF2BP2, showed associations with abdominal total fat and visceral total fat in Canadian Caucasians [26] and Mexican Americans [27] , suggesting a possible role of IGF2BP2 in insulin resistance (IR). Conclusive evidence that polymorphisms within the IGF2BP2 gene affect diabetes susceptibility through changes in the activity of the IGF2BP2 protein per se is lacking, but it seems plausible that IGF2BP2 might influence the development and/or function of the pancreas or adipose tissue through effects on the expression of IGF2 and/or other proteins [28] .
It has been reported that SNP rs4402960 is in high linkage disequilibrium (LD) with rs11705701 G>A, a polymorphic marker located in the promoter region, ~1.48-kb upstream from exon 1 of IGF2BP2 [27] . The diabetes-associated allele A of rs11705701 has been shown to be related to the percentage of body fat, IR [27] , and the expression of a novel short IGF2BP2 isoform that lacks the Nterminal RRM1 motif and that is highly expressed in the pancreatic and adipose tissue [29, 30] . In the present study, we investigated whether the rs4402960 and 11705701 polymorphisms are associated with T2D, diabetesrelated traits, and IGF2BP2 expression levels in adipose tissue derived from Russian diabetic and non-diabetic patients. Hypertension was defined as systolic pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg in at least two separate measurements, or in the case of a history of hypertension. Obesity was defined as BMI ≥ 30 kg/m 2 [33] . The control subjects had no history of glucose intolerance, with HbA1c < 6.4%, normal OGTT, and no family history of diabetes. To avoid interference from biological variables, individuals with a previous diagnosis of type 1 diabetes, gestational diabetes, rare forms of T2D, secondary diabetes (pancreatitis, hemochromatosis), and those with hypercholesterolemia or undergoing treatment with cholesterol-lowering drugs were excluded from the study. The study protocol was approved by the Review Board of the Endocrinology Research Center. All participants provided written informed consent.
Materials and methods

Patients
Biochemical measurements
Plasma glucose was measured by a standard enzymatic assay. Plasma insulin levels were determined by means of an enzymatic immunoassay. Homeostasis model assessment of β-cell function (HOMA-β) was calculated as 20 x fasting plasma insulin (mU/l)/(fasting glucose (mmol/l) -3.5). Homeostasis model assessment of insulin resistance (HOMA-IR) was computed as fasting plasma insulin (mU/l) x fasting glucose (mmol/l)/ 22.5 [34] . HOMA-IR ≥ 3.8 was considered as threshold score reflecting the presence of IR. Clinical and metabolic characteristics of diabetic and non-diabetic subjects are summarized in Table 1 .
Measuring IGF2BP2 protein levels in adipose tissue
IGF2BP2 protein was quantified in human visceral adipose tissue samples. Visceral adipose tissue biopsies were taken from the greater epiploon region. Human adipocytes were isolated by treating the adipose tissue biopsies with Collagenase NB 6 GMP Grade from Clostridium histolyticum (Serva Electrophoresis, Heidelberg, Germany), as described in the manufacturer's protocol [35] . Isolated adipocytes were washed with PBS and then solubilized in the lysis buffer (50 mmol/l HEPES, 150 mmol/l NaCl 2 , 10% (v/v) glycerol, and 1% (v/v) Triton X-100). Cell lysates were centrifuged at 18,000 rpm for 10 min to remove cell debris and unlysed cells. Before loading on SDSpolyacrylamide gel, extracted proteins were mixed with 4 x SDS loading buffer and heated at 95ºC for 5 min.
After electrophoresis, proteins were transferred to Immunobilon polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, NA, USA) for Western blot analysis. The membranes were incubated with antibodies against human IGF2BP2 (Abgent, San Diego, CA, USA) specific to the Cterminal region (dilution 1/5,000). Horseradish peroxidase-coated polyclonal goat anti-IgG antibodies (Thermo Fisher Scientific, Rockford, IL, USA) diluted at 1/1,000 were used as secondary antibodies. Chemiluminiscence, enhanced with Pierce enhanced chemiluminescence (ECL) substrate (Thermo Fisher Scientific), was measured on the chemiluminometer Lumipol 3 (Lumipol Techniques, Bratislava, Slovakia). The recombinant human IGF2BP2 (OriGene Technologies, Rockwell, MD, USA) was used as a positive control.
Quantification of IGF2BP2 expression
IGF2BP2 expression was measured in samples of the human visceral adipose tissue. Total RNA was isolated from adipose tissues with the RNeasy mini kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's protocol, and digested with DNase I (RNase-Free DNase set, Qiagen). RNA quality was evaluated by measuring the 260/280 nm absorbance ratio (≥1.8) and by using electrophoresis. First-strand cDNA was synthesized using an equal amount of total RNA with the High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA, USA). Real-time quantitative polymerase chain reaction (PCR) was performed in a final volume of 20 µl, which contained 10 ng of reverse-transcribed cDNA, 10 µl of 2X Taqman Fast Universal PCR Master Mix (Applied Biosystems), and 1 µl Taqman Assay predesigned by Applied Biosystems for the detection of IGF2BP2, ACTB, and GAPDH (product numbers: Hs01118009_m1, Hs03023880_g1, and Hs02758991_g1, respectively). ACTB and GAPDH were both used as housekeeping genes. All reactions were performed in triplicate, and carried out in 96-well plates by using the 7500 Real-Time PCR System (Applied Biosystems). Real-time PCRs were performed with transcription efficiency >90%. The analysis was performed using the ∆∆CT method [36] .
DNA analysis
Total DNA was isolated from whole-blood samples pretreated with proteinase K using a standard protocol for extraction with phenol-chloroform. Genotyping of rs11705701 and rs4402960 was performed by a Taqman-based allelic discrimination on the 7500 Real-Time PCR System 7500 using the recommended protocol [37] . Overall, genotype calling rates were 98.5% (rs4402960) and 99.1% (rs11705701), respectively.
Statistical analysis
Data were analyzed using SPSS (version 13.0; SPSS Inc., Chicago, IL, USA). Results are given as mean ± SD or percentages. Skewed variables for the continuous traits were log-transformed before statistical comparisons were made. Unpaired Student's t-test was applied to compare quantitative data in the groups of affected and non-affected subjects. Odds ratios (OR) for the risk of developing T2D were calculated using logistic regression, assuming an additive genetic model adjusted for age, sex, HbA1c, hypertension, obesity, and BMI. Multivariate linear regression analysis, adjusted for age, sex, hypertension, obesity, and BMI, was applied to test genotype-phenotype correlations.
The nucleotide sequence flanking rs11705701 was screened for the presence of putative binding sites of transcription factors with the help of the JASPAR database (http://jaspar.cgb.ki.se/). The Microinspector v1.5 program [38] was implemented to search the sequence flanking rs4402960 for possible microRNA binding sites. The 2LD software [39] was used to access LD (measured by D') between rs4402960 and rs11705701.
In the quantitative analysis of IGF2BP2 mRNA and protein, statistical significance of differences between the groups was tested using nonparametric tests: Kruskal-Wallis rank sum test for comparison of three genotypes and Mann-Whitney U-test for comparisons between two groups. Pvalues of less than 0.05 were considered as significant.
Results
For both rs4402960 and rs11705701, observed genotype frequencies were in accordance with the Hardy-Weinberg equilibrium (data not shown).
We found no significant association between rs4402960 and T2D ( Table 2) . SNP rs11705701 of IGF2BP2 showed an association with T2D, with allele A contributing to higher diabetes risk (OR = 1.19, p < 0.001). Since specificity and sensitivity of HbA1c as a screening tool for diabetes diagnosis is limited, we excluded 125 T2D patients whose diagnosis was based on HbA1c alone. However, exclusion of these subjects did not markedly influence the association. For rs4402960, both diabetic and non-diabetic carriers of genotype TT had significantly increased HOMA-IR (p = 0.033 and p = 0.031, respectively), as compared to homozygotes GG and heterozygotes GT (Tables 3-5 ). This observation suggests that rs4402960 of IGF2BP2 is implicated in the development of IR in the population studied.
Compared to the carriers of other rs11705701 genotypes, non-diabetic subjects homozygous for AA showed higher HOMA-IR (p = 0.04), lower HOMA-β (p = 0.012), and reduced 2-h insulin levels (p = 0.016), suggesting an involvement of this IGF2BP2 variant in both IR and impaired β-cell function (Tables 4 and 5 ).
The expression of IGF2BP2 was measured in adipose tissue of obese-and non-obese diabetic patients and control subjects with and without obesity (Table 6 ). ACTB and GAPDH were used as internal controls to normalize quantitative gene expression data. The expression of both genes showed a good replication rate, with a variability between the samples of only 1-5%.
To verify whether different IGF2BP2 isoforms with five or six RNA-binding motifs [30] could arise from the alternative splicing, we generated primers and Taqman probes specific to exon 1, which encodes the first N-terminal 59 amino acids lacking in the truncated IGF2BP2 isoform. However, the expression levels of IGF2BP2, measured by means of exon 1-specific primers, did not differ from IGF2BP2 mRNA amounts quantified using the RT-PCR detection assay (cat. number Hs01118009_m1) from Applied Biosystems (data not shown). The primers and the Taqman probe predesigned by Applied Biosystems are specific to the IGF2BP2 region that differs from exon 1. Indeed, we found that the truncated IGF2BP2 isoform is unlikely to result from the alternatively spliced transcript lacking exon 1.
Overall, IGF2BP2 mRNA levels were significantly elevated in obese diabetic subjects compared to obese controls (7.56 ± 2.75 vs. 3.4 ± 1.56, p = 0.007). Similarly, in adipose tissue of nonobese T2D individuals, IGF2BP2 expression was higher than that in non-obese controls (6.1 ± 2.53 vs. 2.17 ± 1.19, p = 0.011). Non-obese individuals (diabetic and non-diabetic) homozygous for either AA (rs11705701) or TT (rs4402960) had increased levels of IGF2BP2 mRNA in adipocytes compared to other IGF2BP2 variants (Table 6 ). However, we did not find any significant difference in IGF2BP2 expression in obese patients carrying different rs11705701 and rs4402960 genotypes. The role of the stimulatory effect of the T allele of rs4402960 on IGF2BP2 expression is unclear because this polymorphism is located in the long, non-coding intron 2, at nucleotide 29,254, distinct from exon 2. We tested whether the nucleotide variation at rs4402960 may alter a putative binding site for microRNA. In the vicinity of rs4402960, we found two potential binding sequences for hsa-miR-4646-3p and hsa-miR-197 (in 6 and 9 nucleotides upstream from the polymorphic site). However, none of these sequences could be influenced by rs4402960.
The rs11705701 is located in the 5' promoter region of IGF2BP2, approximately 1.48 kb upstream of exon 1 and 32.62 kb apart from rs4402960. We did not observe any significant pairwise LD between these polymorphic markers (D' = 0.53, p = 0.22). We found that allele G of rs11705701 may disrupt a potential sequence for binding transcription factors NFIC (atggcA, score 0.88) and ETS1 (Aatcct, score 0.90). This could explain the activating effects of minor allele A in IGF2BP2 transcription. However, it is necessary to test whether these transcription factors stimulate the expression of IGF2BP2.
Using anti-IGF2BP2 antibodies specific to the C-terminal region of this protein, we were able to detect both IGF2BP2 isoforms (p58 and p66) in the adipose tissue (Figure 1) . The recombinant IGF2BP2 purchased in OriGene Technologies was used as a positive control, and revealed a single full-length protein isoform p66. We found that the short isoform p58 can constitute a significant percentage (up to 45%) of a total IGF2BP2 protein in the adipose tissue. In total, average IGF2BP2 levels did not significantly differ between non-obese and obese diabetic patients. Similarly, there were no significant differences between adipose IGF2BP2 protein levels between non-obese and obese non-diabetic controls. Compared to control subjects, adipose tissue of T2D patients involved a 2-fold increased IGF2BP2 protein level (32.6 ± 18.5 pg/mg tissue vs. 17.1 ± 7.9 pg/mg tissue, p = 0.0003) as a consequence of enhanced expression of this factor in the diabetic adipose tissue.
We also tested whether polymorphic variants of IGF2BP2 were associated with IGF2BP2 protein levels in adipocytes, but we found no significant correlation between IGF2BP2 protein amounts and rs4402960 (Table 7) . In contrast, in non-obese individuals (both diabetic and non-diabetic) homozygous for AA of rs11705701, p58 isoform levels were reduced, while p66 was significantly increased in comparison with other rs11705701 variants. In obese subjects, we found no correlation between the p66 levels and rs11705701, while p58 was significantly reduced in both diabetic and non-diabetic carriers of genotype AA compared with AG and GG carriers (Table 7) . Since we observed a reverse correlation between isoform p58 levels and the presence of the disease-predisposing allele A, this isoform may play a protective role against T2D.
Discussion
Despite repeated demonstration of an association of rs4402960 of IGF2BP2 with diabetes in many populations, there was no significant correlation in our Russian population. In agreement with our finding, several large-scale population studies reported a lack of association in some Caucasian groups, including Frenchmen [40, 41] , Islanders [42] , and US Whites [43] . The IGF2BP2 variant has a very small effect in T2D. Based on all studies, the reported association with the IGF2BP2 locus (OR 1.14, 95% CI 1.10-1.17) represents a difference in allele frequency of only 3% between case and control groups in over 34,000 subjects [41] . Thus, a significant increase in population size is needed to detect the effect of this IGF2BP2 genetic variant.
Despite the lack of association between the rs4402960 IGF2BP2 variant and diabetes, we found a significant association between another IGF2BP2 marker (rs11705701) and T2D. The minor alleles of both SNPs were associated with increased HOMA-IR, suggesting that IGF2BP2 is involved in the development of IR in a Russian population. In line with this finding, Li et al. reported a relationship between rs11705701 and adiposity detected by an association with abdominal and visceral total fat [27] . It is likely that the association between IGF2BP2 polymorphic markers and IR could be explained, at least in part, by correlation between the presence of the genotype TT (rs4402960) and/or AA (rs11705701) and increased levels of IGF2BP2 mRNA in adipose tissue. We observed a more than two-fold increase in IGF2BP2 expression levels in the adipose tissue of diabetic patients compared to controls. Similarly, Parikh et al. detected altered expressions of IGF2BP2 in adipocytes of T2D subjects compared with healthy people [44] . In two other studies, augmented expression of IGF2BP2 has been shown in the pancreas of T2D patients [45, 46] . Jin et al. reported upregulated expression of IGF2BP2 in peripheral monocytes of monkeys fed with a high-fat diet [47] .
IGF2 plays a pivotal role in regulating fetal growth and organogenesis, including adipogenesis [48] and pancreatic development [49] . In GotoKakizaki rats, a spontaneous model for T2D, suppression of IGF2 production in embryonic pancreas results in lowered β-cell mass that precedes the onset of hyperglycemia [50] . Since IGF2BPs repress translation at late developmental stages [1] , fetal overproduction of IGF2BP2 in pancreatic and adipose tissues could downregulate the translation of IGF2 mRNA at earlier prenatal steps, and thus lead to abnormalities in the development of pancreas and adipocytes. Generally, IGF2 shortage may contribute to reduced birthweight that is considered an independent risk factor for T2D [51] .
Van Hoek et al. detected a nominally significant role of rs4402960 of IGF2BP2 and its interaction with intrauterine malnutrition to early induction of glucose intolerance [52] . Impaired islet β-cell development leads to impairment in insulin secretion, thereby promoting the manifestation of hyperglycemia and IR [53] . Association of rs4402960 with T2D may be realized not only through impaired β-cell development and function, but also through alterations in adipose tissue [27] .
In our study, we confirmed recent data from Li et al. who detected the existence of two isoforms of IGF2BP2 generated by alternative translation ini- tiation [27] . The isoforms are abundantly distributed in different tissues, preferentially in adipose and pancreatic tissues. We found that adipose levels of the short IGF2BP2 isoform p58, having a molecular weight of 58 kDa and lacking the first 58 amino acids, can be modulated by the rs11705701 polymorphism of IGF2BP2. The first RRM domain of IGF2BP2, which is absent in the small isoform, contains highly conserved RNP1 and RNP2 motifs important for RNA recognition, in contrast to the second RRM domain, which has poor RNA-binding signatures [54] . In addition to binding to RNA, RRM domains can participate in protein-protein interaction and facilitate inter-or intra-molecular dimerization of RRM domain-containing proteins [54] . Thus, loss of the RRM1 domain in the small isoform might affect its binding affinity and specificity to both RNA and protein partners. It may also affect its own structure, dimer formation, and stability.
Compared to the canonic full-length isoform p66 that has six RNA-binding motifs, the truncated isoform p58 may have decreased RNAbinding capacity and reduced affinity to IGF-2 mRNA. Due to the less efficient capacity of the short isoform to downregulate translation of IGF-2 mRNA, this mRNA would be better translated to produce more IGF-2, and in turn, to improve insulin action in peripheral tissues. In the context of diabetes, reduced levels of p58 accompanied with increased production of IGF2BP2 isoform p66 could predispose to the development of IR by im- Table 7 . Levels of IGF2BP2 protein isoforms in adipose tissue of obese and non-obese diabetic and non-diabetic carriers of different genotypes of rs4402960 and rs11705701 pairing insulin action in the adipose tissue of carriers of the genotype AA of 11705701.
